The Role of cTA™ In Bringing IO 360° Full Circle

The 3rd annual Immuno-Oncology 360° meeting, #IO360nyc, took a 360-degree view of the IO space with the first day dedicated to science, the second to clinical data, and the third to the “business” landscape. 

With over 800 clinical trials in process for combination IO therapeutics and almost no holds for toxic events, it is estimated that approximately 80 FDA approvals will be issued over the next two to four years[…]

Read More